Get the Stockscreener App
3.14
0.32%
0.01
After Hours:
3.18
0.04
+1.27%
Tharimmune Inc stock is traded at $3.14, with a volume of 720.53K.
It is up +0.32% in the last 24 hours and up +124.29% over the past month.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
See More
Previous Close:
$3.13
Open:
$3.32
24h Volume:
720.53K
Relative Volume:
0.08
Market Cap:
$17.87M
Revenue:
-
Net Income/Loss:
$-9.32M
P/E Ratio:
-0.247
EPS:
-12.7107
Net Cash Flow:
$-7.30M
1W Performance:
-14.67%
1M Performance:
+124.29%
6M Performance:
+122.70%
1Y Performance:
+5.02%
1-Day Range:
$3.13
$3.4599
1-Week Range:
$2.75
$3.63
52-Week Range:
$0.952
$9.08
Tharimmune Inc Stock (THAR) Company Profile
Name
Tharimmune Inc
Sector
Industry
Phone
302-743-2995
Address
1200 ROUTE 22 EAST, BRIDGEWATER
Compare THAR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
THAR
Tharimmune Inc
|
3.14 | 16.28M | 0 | -9.32M | -7.30M | -12.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Tharimmune Inc Stock (THAR) Latest News
Ranking Tharimmune Inc. among high performing stocks via tools2025 Major Catalysts & Free Growth Oriented Trading Recommendations - Newser
Has Tharimmune Inc. found a price floorJuly 2025 Drop Watch & AI Optimized Trading Strategy Guides - Newser
Using flow based indicators on Tharimmune Inc.Portfolio Risk Summary & Real-Time Market Trend Scan - Newser
What to expect from Tharimmune Inc. in the next 30 days2025 Trading Volume Trends & Weekly High Potential Alerts - Newser
What technical models suggest about Tharimmune Inc.’s comebackJuly 2025 Analyst Calls & Real-Time Stock Price Movement Reports - Newser
Is Tharimmune Inc. stock ready for a breakout2025 Earnings Impact & Weekly High Momentum Picks - Newser
Will breakout in Tharimmune Inc. lead to full recovery2025 Dividend Review & Stepwise Trade Execution Plans - Newser
Using data filters to optimize entry into Tharimmune Inc.Portfolio Return Summary & Daily Profit Focused Screening - Newser
can tharimmune inc. hit a new high this monthPortfolio Return Report & Safe Entry Zone Identification - Newser
Can machine learning forecast Tharimmune Inc. recoveryJuly 2025 Institutional & Technical Confirmation Alerts - Newser
Has Tharimmune Inc. formed a bullish divergence2025 Geopolitical Influence & Stepwise Swing Trade Plans - Newser
Will Tharimmune Inc. bounce back from current support2025 Technical Patterns & Risk Controlled Daily Trade Plans - Newser
Is Tharimmune Inc. reversing from oversold territoryGold Moves & Long-Term Growth Portfolio Plans - Newser
Top chart patterns to watch in Tharimmune Inc.Long Setup & Fast Momentum Entry Tips - Newser
Tharimmune Secures Nasdaq Listing with $7.05M Raise - MSN
Risk adjusted return profile for Tharimmune Inc. analyzedJuly 2025 Analyst Calls & Safe Capital Growth Plans - Newser
Statistical indicators supporting Tharimmune Inc.’s strengthEarnings Risk Report & Fast Entry High Yield Stock Tips - Newser
What data driven models say about Tharimmune Inc.’s futureShort Setup & Smart Money Movement Alerts - Newser
Can you recover from losses in Tharimmune Inc.Trade Risk Summary & High Accuracy Trade Alerts - Newser
Can Tharimmune Inc. hit a new high this monthEarnings Recap Summary & Short-Term High Return Strategies - Newser
Is Tharimmune Inc. trending in predictive chart models2025 Volume Leaders & Free Real-Time Volume Trigger Notifications - Newser
News impact scoring models applied to Tharimmune Inc.Layoff News & Risk Controlled Stock Pick Alerts - Newser
Chart based analysis of Tharimmune Inc. trendsTreasury Yields & Real-Time Chart Pattern Alerts - Newser
Sentiment analysis tools applied to Tharimmune Inc.Trade Ideas & Weekly Breakout Opportunity Watchlist - Newser
Visual trend scoring systems applied to Tharimmune Inc.Trade Risk Assessment & Advanced Swing Trade Entry Plans - Newser
What machine learning models say about Tharimmune Inc.July 2025 Analyst Calls & Low Risk High Reward Ideas - Newser
Tharimmune Inc. stock volume spike explainedWatch List & Real-Time Volume Trigger Notifications - Newser
Is Tharimmune Inc. meeting your algorithmic filter criteriaMarket Trend Report & Long-Term Capital Growth Ideas - Newser
Multi factor analysis applied to Tharimmune Inc.Gap Up & Real-Time Buy Signal Alerts - Newser
Tharimmune raises executive salaries and adjusts change of control terms By Investing.com - Investing.com UK
Tharimmune raises executive salaries and adjusts change of control terms - Investing.com
Tharimmune Inc Stock (THAR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):